Pathogenesis of Guillain-Barré syndrome

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 4, 2003, Pages 597-608

  Tsang, Raymond S W ^a   Valdivieso Garcia, Alfonso ^b  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b HEALTH CANADA   (Canada)

Author keywords

Autoimmunity; Cytokines; GBS; Pathogenesis; Therapeutics

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; CYTOKINE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; RECEPTOR; ROQUINIMEX;

AUTOIMMUNE DISEASE; DISEASE COURSE; GUILLAIN BARRE SYNDROME; HOST PARASITE INTERACTION; HUMAN; IMMUNE RESPONSE; MEDIATOR; OUTCOMES RESEARCH; PATHOGENESIS; PLASMAPHERESIS; REVIEW;

EID: 3042739100     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.4.597     Document Type: Review

References (110)

1. Guillain G, Barré JA, Strohl A. Sur un syndrome de radioculo-nevrite avec huyperalbuminose du liquide cephalorachidien sans reaction cellulaire: Remarques sur les caracters cliniques et graphiques des reflexes tendineux. Bull. Soc. Med. Hop. Paris 40, 1462-1470 (1916).
2. Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann. Neurol. 27, S21-S24 (1990).
3. Thomas PK. The Guillain-Barré Syndrome: no longer a simple concept. J. Neurol. 239, 361-362 (1992).
4. Asbury AK. New concepts of Guillain-Barré syndrome. J. Child. Neurol. 15, 183-191 (2000).
5. Ad Hov Committee WHO-AIREN. Acute onset flaccid paralysis. World Health Organization, Geneva, Switzerland (1993).
6. Asbury AK, McKhann GM. Changing views of Guillain-Barré syndrome. Ann. Neurol. 41, 287-288 (1997).
7. Van der Meche FG, Van Doom PA, Meulstee J, Jennekens FG, the GBS-consensus group of the Dutch Neuromuscular Research Support Centre. Diagnostic and classification criteria for the Guillain-Barré Syndrome. Eur. Neurol. 45, 133-139 (2001).
8. Dingle KE, Van Den Braak N, Colles FM et al. Sequence typing confirms that Campylobacter jejuni strains associated with Guillain-Barré and Miller-Fisher syndromes are of diverse generic lineage, seortype and flagella type. J. Clin. Microbiol. 39, 3346-3349 (2001).
9. Yuki N. Infectious origins of and molecular mimicry in, Guillain-Barré and Fisher syndromes. Lancet Infect. Dis. 1, 29-37 (2001).
10. Jacobs BC, Rothbarth PH, van der Meche FG et al. The spectrum of antecedent infections in Guillain-Barré syndrome: a case-control study. Neurology 51, 1110-1115 (1998).
11. Hadden RD, Karch H, Hartung HP. Preceding infections, immune factors and outcome in Guillain-Barré syndrome. Neurology 56, 758-765 (2001).
12. Tsang RSW. The relationship of Campylobacter jejuni infection and the development of Guillain-Barré syndrome. Curr. Opin. Infect. Dis. 15, 221-228 (2002).
13. Visser LH, van der Meche FG, Meulstee J et al. Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiological and prognostic features, Dutch Guillain-Barré Study Group. Neurol. 47, 668-673 (1996).
14. Griffin JW, Li CY, Ho TW et al. Guillain-Barré syndrome in northern China, the spectrum of neuropathologic changes in clinically defined cases. Brain 118, 577-595 (1995).
15. Lu JL, Sheikh KA, Wu HS et al. Physiologic-pathologic correlation in Guillain-Barré syndrome. Neurology 54, 33-39 (2000 ).
16. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine 48, 173-215 (1969).
17. Hafer-Macko C, Hsieh ST, Li CY et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann. Neurol. 40, 635-644 (1996).
18. Ho TW, Willison HJ, Nachamkin I et al. AntiGD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann. Neurol. 45, 168-173 (1999).
19. Gold R, Hartung HP, Toyka KV. Animal models for autoimmune demyelinating disorders of the nervous system. Mol. Med. Today 6, 88-91 (2000).
20. Brostoff SW, Levit S, Powers JM. Induction of experimental allergic neuritis with a peptide from myeline P2 basic protein. Nature 268, 752-753 (1977).
21. Linington C, Lassmann H, Ozawa K, Kosin S, Mongan L. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by P0 protein-specific T-cell lines. Eur. J. Immunol. 22, 1813-1817 (1992).
22. Abromson-Leeman S, Bronson R, Dorf ME. Experimental autoimmune peripheral neuritis induced in Balb/c mice by myelin basic protein-specific T-cell clones. J. Exp. Med. 182, 587-592 (1995).
23. Gabriel CM, Hughes RA, Moore SE, Smith KJ, Walsh FS. Induction of experimental autoimmune neuritis with peripheral myelin protein-22. Brain 121, 1895-1902 (1998).
24. Weerth S, Berger T, Lassmann H, Linington C. Encephalitogenic and neuritogenic T-cell responses to the myelinassociated glycoprotein (MAG) in the Lewis rat. J. Neuroimmunol. 95, 157-164 (1999).
25. Heininger K, Stoll G, Linington C, Toyka KV, Wekerle H. Conduction failure and nerve conduction slowing in experimental allergic neuritis induced by P2-specific T-cell lines. Ann. Neurol. 19, 44-49 (1986).
26. Previtali SC, Feltri ML, Archelos JJ, Quattrini A, Wrabetz L, Hartung HP. Role of integrins in the peripheral nervous system. Prog. Neurbiol. 64, 35-49 (2001).
27. Ho TW, McKhann GM, Griffin JW. Human antoimmune neuropathies. Ann. Rev. Neurosci. 21, 187-226 (1998).
28. Press R, Mara S, Lolli F, Zhu J, Andersson T, Link H. Temporal profile of antiganglioside antibodies and their relation to clinical parameters and treatment in GBS. J. Neurol. Sci. 190, 41-47 (2001).
29. Van Koningsveld R, Schmitz PI, Ang CW et al. Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurolog 58, 610-614 (2002).
30. Gilbert M, Brisson JR, Karwaski MF et al. Biosynthesis of ganglioside mimics in Campylobacter jejuni. J. Biol. Chem. 275, 3896-3906 (2000).
31. Moran AP, Prendergast MM. Molecular mimicry in Campylobacter jejuni and Helicobacter pylori lipopolysaccharides: contribution of gastrointestinal infections to autoimmunity. J. Autoimmun. 16, 241-256 (2001).
32. Kusunoki S, Shiina M, Kanazawa I. AntiGal-C antibodies in GBS subsequent to mycoplasma infection: evidence of molecular mimicry. Neurology 57, 736-738 (2001).
33. Yuki N, Yamada M, Koga M et al. Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol. 49, 712-720 (2001).
34. Plomp JJ, Molenaar PC, O'Hanlon GM et al. Miller Fisher antiGQ1b antibodies: α-latrotoxin-like effects on motor-end plates. Ann. Neurol. 45, 189-199 (1999).
35. Yan WX, Taylor J, Andrias-Kauba S, Pollard JD. Passive transfer of demyelination by serum or IgG from chronic inflammatory demyelinating polyneuropathy patients. Ann. Neurol. 47, 765-775 (2000).
36. The Guillain-Barre Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 35, 1096-1104 (1985).
37. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barre Study Group. N. Engl. J. Med. 328, 1123-1129 (1992).
38. Sheikh KA, Griffin JW. Variants of the Guillain-Barré syndrome: progress toward fulfilling Koch's postulates. Ann. Neurol. 49, 694-696 (2001).
39. Kusunoki S. Antiglycolipid antibodies in Guillain-Barré syndrome and autoimmune neuropathies. Am. J. Med. Sci. 319, 234-239 (2000).
40. Chiba A, Kusunoki S, Shimizu S, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible market of Miller Fisher syndrome. Ann. Neurol. 31, 677-479 (1992).
41. Willison HJ, Veitch J, Patterson G, Kennedy PG. Miller Fisher syndrome is associated with serum antibodies to GQ1b ganglioside. J. Neurol. Neurosurg. Psychiatry 56, 204-206 (1993).
42. Jacobs BC, Bullens RW, O'Hanlon GM, Ang CW, Willison HJ, Plomp JJ. Detection and prevalence of α-latrotoxin-like effects of serum from patients with Guillain-Barré syndrome. Muscle Nerve 25, 549-558 (2002).
43. Yuki N, Ang CW, Koga M et al. Clinical features and response to treatment in Guillain Barré syndrome associated with antibodies to GM1b ganglioside. Ann. Neurol. 47, 314-321 (2000).
44. Koga M, Yoshino H, Morimatsu M, Yuki N. AntiGT1a IgG in Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry 72, 767-771 (2002).
45. Yuki N, Yoshino H, Sato S, Shinozawa K, Miyatake T. Severe acute axonal form of Guillain-Barré syndrome associated with IgG antiGD1a antibody. Muscle Nerve 15, 899-903 (1992).
46. Hao Q, Saida T, Yoshino H, Kuroki S, Nukina M, Saida K. AntiGalNAc-GD1a antibody-associated Guillain-Barré syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance. Ann. Neurol. 45, 758-768 (1999).
47. Kwa MS, van Schaik IN, De Jonge RR et al. Autoimmunoreactivity in Schwann cells in patients wth inflammatory neropathies. Brain 126, 361-375 (2002).
48. Ang CW, Laman JD, Willison HJ et al. Structure of Campylobacter jejuni lipopolysaccharides determines antiganglioside specificity and clinical features of Guillain-Barré and Miller Fisher patients. Infect. Immun. 70, 1202-1208 (2002).
49. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res. 745, 32-36 (1997).
50. Hanlon GM, Plomp JJ, Chakfrabarti M et al. AntiGQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal. Brain 124, 893-906 (2001).
51. Mori M, Kuwabara S, Miyake M et al. Haemophilus influenzae has a GM1 ganglioside-like structure and elicits Guillain-Barré syndrome. Neurology 52, 1282-1284 (1999).
52. Schmidt B, Toyka KV, Kiefer R, Full J, Hartung HP, Pollard J. Inflammatory infiltrates in sural nerve biopsies in Guillain-Barré syndrome and chronic inflammatory demyelinating neuropathy. Muscle Nerve 19, 474-487 (1996).
53. Khalili Shirazi A, Hughes RA, Brostoff SW, Linington C, Gregson N. T-cell responses to myelin proteins in Guillain-Barré syndrome. J. Neurol. Sci. 111, 200-203 (1992).
54. Van Rhijn I, Bleumink-Pluym NM, Van Putten JP, Van den Berg LH. Campylobacter DNA is present in circulating myelomonocytic cells of healthy persons and in persons with Guillain-Barré syndrome. J. Infect. Dis. 185, 262-265 (2002).
55. Cooper JC, Ben-Smith A, Savage CO, Winer JB. Unusual T-cell receptor phenotype V gene usage of γδ T-cells in a line derived from the peripheral nerve of a patient with Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry 69, 522-524 (2001).
56. Ilyas AA, Chen ZW, Cook SD, Mithen FA, Singhal BS. Immunoglobutin G subclass distribution and autoantibodies to gangliosides in patients with Guillain-Barré syndrome. Res. Commun. Mol. Pathol. Pharmacol. 109, 115-123 (2001).
57. Sieling PA, Chatterjee D, Porcelli SA et al. CD1-restricted T-cell recognition of microbial lipoglycan antigens. Science 269, 227-230 (1995).
58. Khalili-Shirazi A, Gregson NA, Londel M, Summers L, Hughes RA. The distribution of CD1 molecules in inflammatory neuropathy. J. Neurol. Sci. 158, 154-163 (1998).
59. Linington C, Izumo S, Suzuki M, Uyemura K, Meyermann R, Wekerle H. A permanent rat T-cell line that mediates experimental allergic neuritis in the Lewis rat in vivo. J. Immunol. 133, 1946-1950 (1984).
60. Brosnan JV, Craggs RI, King RH, Thomas PK. Reduced susceptibility of T-cell deficient rats to induction of experimental allergic neuritis. J. Neuroimmunol. 14, 267-282 (1987).
61. Jung S, Kramer S, Schluesener HJ, Hunig T, Toyka K, Hartung HP. Prevention and therapy of experimental autoimmune neuritis by an antibody against T-cell receptor-α/β J. Immunol. 148, 3768-3775 (1992).
62. Hartung HP, Schafer B, Diamantstein T, Fierz W, Heininger K, Toyka KV. Suppression of P2-T-cell line-mediated experimental autoimmune neuritis by interleukin 2 receptor targeted monoclonal antibody ART. Brain Res. 489, 120-128 (1989).
63. Zhu Y, Ljunggren H-G, Mix E et al. CD28-B7 costimulation: a critical role for initation and development of experimental autoimmune neuritis in C57BL/6 mice. J. Neuroimmunol. 114, 114-121 (2001).
64. Zhu Y, Bao L, Zhu S et al. CD4 and CD8 T-cells but not B-cells, are critical to the control of murine experimental autoimmune neuritis. Exp. Neurol. 177, 314-320 (2002).
65. Hartung HP, Willson, HJ, Keiseier BC. Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome. Curr. Opin. Neurol. 15, 571-577 (2002).
66. Orlikowski D, Chazaud B, Plonquet A et al. Monocyte chemoattractant protein 1 and chemokine receptor CCR2 productions in Guillain-Barré syndrome and experimental autoimmune neuritis. J. Neuroimmunol. 134, 118-127 (2003).
67. Kieseier BC, Tani M, Mahad D et al. Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. Brain 125, 823-834 (2002).
68. Zou LP, Pelidou SH, Abbas N et al. Dynamics of production of MIP-1α, MCP-1 and MIP-2 and potential role of neutralization of these chemokines in the regulation of immune responses during experimental autoimmune neuritis in Lewis rats J. Neuroimmunol. 98, 168-175 (1999).
69. Stoll G. Inflammatory cytokines in the nervous system: multifunctional mediators in autoimmunity and cerebral ischaemia. Rev. Neurol. 158, 887-891 (2002).
70. Mossman TR, Fowell DJ. The Th1/Th2 paradigm in infections. In: Immunology and Infectious Disease. Kaufmann SHE, Sher A, Ahmed R (Eds). ASM Press, London, UK 163-174 (2002).
71. Jander S, Stoll G. Interleukin-18 is induced in acute inflammatory demyelinating polyneuropathy. J. Neuroimmunol. 114, 253-258 (2001).
72. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ. Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann. Neurol. 53, 174-180 (2003).
73. Yu S, Chen Z, Mix E et al. Neutralizing antibodies to IL-18 ameliorate experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen. J. Neuropathol. Exp. Neurol. 61, 614-622 (2002).
74. Zhu J, Bai XF, Mix E, Link H. Cytokine dichotomy in the peripheral nervous system influences the outcome of experimental allergic neuritis: dynamics of mRNA expression for IL-1β, IL-6, IL-10, IL-12, TNF-α and TNF-β and cytolysin. Clin. Immunol. Immunopathol. 84, 85-94 (1997).
75. Pelidou SH, Zou LP, Deretzi G et al. Intranasal administration of recombinant IL-12 increases inflamation and demyelination in chronic experimental autoimmune neuritis in Lewis rats. Scand. J. Immunol. 51, 29-35 (2000).
76. Bao L, Lindgren JU, van der Meide P, Zhu S, Ljunggren HG, Zhu J. The critical role of IL-12p4O in initiating, enhancing and perpetuating pathogenic events in murine experimental autoimmune neuritis. Brain Pathol. 12, 420-429 (2002).
77. Press R, Deretzi G, Zou LP et al. IL-10 and IFN-γ in Guillain-Barré syndrome. Network Members of the Swedish Epidemiological Study Group. J. Neuroimmunol. 112, (129-138 (2001).
78. Laura M, Gregson NA, Curmi Y, Hughes RA. Efficacy of leukemia inhibitory factor in experimental autoimmune neuritis. J. Neuroimmunol. 133, 56-59 (2002).
79. Kurek JB, Radford AJ, Crump DE et al. LIF (AM424), a promising growth factor for the treatment of ALS. J. Neurol. Sci. 160(Suppl. 1), S106-S113 (1998).
80. Sharief MK, Mclean B, Thompson EJ. Circulating tumor necrosis factor-α correlates with electrodiagnostic abnormalities in Guillain-Barré syndrome. Ann. Neurol. 42, 68-73 (1997).
81. Bao L, Lindgren JU, Zhu Y, Ljunggren HG, Zhu J. Exogenous soluble tumor necrosis factor receptor Type 1 ameliorates murine experimental autoimmune neuritis. Neurobiol. Dis. 12, 73-81 (2003).
82. Beg AA, Finco TS, Nantermet PV, Baldwin AS Jr. Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of 1 κ Bα: a mechanism for NF-κ B activation. Mol. Cell. Biol. 13, 3301-3310 (1993).
83. Kohno Y, Kataoka J, Ohtsuki T et al. IFN-α-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. 158, 1541-1550 (1997).
84. Olee T, Hashimoto S, Quach J, Lotz M. IL-18 is produced by articular chondrocytes and induces pro-inflammatory and catabolic responses. J. Immunol. 162, 1096-1100 (1999).
85. Yu S, Chen Z, Mix E et al. Neutraizing antibodies to IL-18 ameliorates experimental autoimmune neuritis by counter-regulation of autoreactive Th1 responses to peripheral myelin antigen. J. Neuropathol. Exp. Neurol. 61, 614-623 (2002).
86. Trinchieri G. Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv. Immunol. 70, 83-243 (1998).
87. Deretzi G, Zou LP, Pelidou SH et al. Nasal administration of recombinant IL-4 ameliorates ongoing experimental autoimmune neuritis and inhibits demyelination. J. Autoimmun. 12, 81-89 (1999).
88. Bai XF, Zhu J, Zhang GX et al. IL-10 suppresses experimental autoimmune neuritis and downregulates Th-1 type immune responses. Clin. Immunol. Immunopathol. 83, 117-126 (1997).
89. Zhu J, Mix E, Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J. Neuroimmunol. 84, 40-52 (1998).
90. Cunningham MW. Cardiac myosin and the Th1/Th2 paradigm in autoimmune myocarditis. Am. J. Pathol. 159, 5-12 (2001).
91. Govoni V, Granieri E. Epidemiology of the Guillain-Barré syndrome. Curr. Opin. Neurol. 14, 605-613 (2001).
92. Ang CW, van Doorn PA, Endtz HP et al. A case of Guillain-Barré syndrome following a family outbreak of Campylobacter jejuni enteritis. J. Neuroimmunol. 111, 229-233 (2000).
93. Hughes RA, Rees JH. Clinical and epidemiological features of Guillain-Barré syndrome. J. Infect. Dis. 176(Suppl. 2), S92-S98 (1997).
94. Dahlman I, Wallstrom E, Jiao H, Luthman H, Olsson T, Weissert R. Phylogenic control of autoimmune peripheral nerve inflammation in rat. J. Neuroimmunol. 119, 166-174 (2001).
95. Koga M, Yuki N, Kashiwase K, Tadokoro K, Juji T, Hirata K. Guillain-Barré and Fisher's syndromes subsequent to Campylobacter jejuni enteritis are associated with HLA-B54 and Cw1 independent of antiganglioside antibodies. J. Neuroimmunol. 88, 62-66 (1998).
96. Rees JH, Vaughan RW, Kondeatis E, Hughes RA. HLA-class II alleles in Guillain-Barré syndrome and Miller Fisher syndrome and their association with preceding Campylobacter jejuni infection. J. Neuroimmunol. 62, 53-57 (1995).
97. Magira EE, Papaiakim M, Nachamkin I et al. Differential distribution of HLA-DQ β/DR beta epitopes in the two forms of Guillain-Barre syndrome, acute motor axonal neuropathy and acute inflammatory demyelinating polyneuropathy (AIDP): identification of DQ β epitopes associated with susceptibility to and protection from AIDP. J. Immunol. 170, 3074-3080 (2003).
98. van der Pol WL, van den Berg LH, Scheepers RH et al. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barré Syndrome. Neurology 54, 1661-1665 (2000).
99. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin and combined treatments in Guillain-Barre syndrome. Lancet 349, 225-230 (1997).
100. Guillain-Barre Syndrome Steroid Therapy Group. Double-blind trail of intravenous methylprednisolone in Guillain-Barre syndrome. Lancet 341, 586-590 (1993).
101. van Koningsveld RM, Schmitz PI, van Doorn PA. Combined therapy of intravenous immune globulin and methylprednisolone in patients with Guillain-Barre Syndrome. The results of a multicentre double-blind controlled clinical trial. J. Peripher. Nerv. Syst. 41, 586-590 (2001) (Abstract).
102. King RHM, Craggs RI, Gross MLP, Thomas PK. Effects of glucocorticoids on experimental allergic neuritis. Exp. Neurol. 87, 9-19 (1985).
103. Dalakas MC. Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59, S13-S21 (2002).
104. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome. Ann. Neurol. 51, 673-680 (2002).
105. Kambara C, Matsuo, H, Fukudome T, Goto H, Shibuya N. Miller Fisher syndrome and plasmapheresis, Ther. Apher. 6, 450-453 (2002).
106. Diener HC, Haupt WF, Moss TM et al. A preliminary, randomized, multicenter study comparing intravenous immunoglobulin, plasma exchange and immune adsorption in Guillain-Barré syndrome. Eur. Neurol. 46, 107-108 (2001).
107. Sdchaller B, Radziwill AJ, Stock AJ. Successful treatment of Guillain-Barré syndrome with combined administration of interferon-β-1a and intravenous immunoglobulin. Eur. Neurol. 46, 167-168 (2001).
108. Wollinsky KH, Husler PJ, Brinkmeier H et al. CSF filtration is an effective treatment of Guillain-Barré syndrome. Neurology 57, 774-780 (2001).
109. Zou LP, Abbas N, Volkmann I et al. Suppression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th2 balance and inhibited migration of inflammatory cells in the peripheral nerve tissue. Neuropharmacology 42, 731-739 (2002).
110. Li CY, Xue P, Tian WQ, Liu RC, Yang C. Experimental Campylobacter jejuni infection in the chicken: an animal model of axonal Guillain-Barré syndrome. J. Neurol. Neurosurg. Psychiatry 61, 279-284 (1996).